110 related articles for article (PubMed ID: 9741956)
21. Modulation of P450-dependent ifosfamide pharmacokinetics: a better understanding of drug activation in vivo.
Brain EG; Yu LJ; Gustafsson K; Drewes P; Waxman DJ
Br J Cancer; 1998 Jun; 77(11):1768-76. PubMed ID: 9667645
[TBL] [Abstract][Full Text] [Related]
22. High-performance liquid chromatographic-fluorescent method to determine chloroacetaldehyde, a neurotoxic metabolite of the anticancer drug ifosfamide, in plasma and in liver microsomal incubations.
Huang Z; Waxman DJ
Anal Biochem; 1999 Aug; 273(1):117-25. PubMed ID: 10452807
[TBL] [Abstract][Full Text] [Related]
23. In vitro rat hepatic and intestinal metabolism of the organophosphate pesticides chlorpyrifos and diazinon.
Poet TS; Wu H; Kousba AA; Timchalk C
Toxicol Sci; 2003 Apr; 72(2):193-200. PubMed ID: 12655035
[TBL] [Abstract][Full Text] [Related]
24. Trofosfamide metabolism in different species--ifosfamide is the predominant metabolite.
Boos J; Küpker F; Blaschke G; Jürgens H
Cancer Chemother Pharmacol; 1993; 33(1):71-6. PubMed ID: 8269592
[TBL] [Abstract][Full Text] [Related]
25. Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics.
Chen CS; Lin JT; Goss KA; He YA; Halpert JR; Waxman DJ
Mol Pharmacol; 2004 May; 65(5):1278-85. PubMed ID: 15102956
[TBL] [Abstract][Full Text] [Related]
26. Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N-dechloroethylation of trofosfamide.
May-Manke A; Kroemer H; Hempel G; Bohnenstengel F; Hohenlöchter B; Blaschke G; Boos J
Cancer Chemother Pharmacol; 1999; 44(4):327-34. PubMed ID: 10447581
[TBL] [Abstract][Full Text] [Related]
27. Expression and function of three cytochrome P-450 isozymes in rat extrahepatic tissues.
Christou M; Wilson NM; Jefcoate CR
Arch Biochem Biophys; 1987 Nov; 258(2):519-34. PubMed ID: 3118810
[TBL] [Abstract][Full Text] [Related]
28. Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines.
Madani S; Paine MF; Lewis L; Thummel KE; Shen DD
Pharm Res; 1999 Aug; 16(8):1199-205. PubMed ID: 10468020
[TBL] [Abstract][Full Text] [Related]
29. Extrahepatic microsomal metabolism of N-nitrosodi-n-butylamine in rats.
Richter E; Schulze J; Zwickenpflug W
IARC Sci Publ; 1987; (84):156-8. PubMed ID: 3679357
[TBL] [Abstract][Full Text] [Related]
30. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles.
Roy P; Yu LJ; Crespi CL; Waxman DJ
Drug Metab Dispos; 1999 Jun; 27(6):655-66. PubMed ID: 10348794
[TBL] [Abstract][Full Text] [Related]
31. Phase I metabolism of imipramine by microsomes of small intestine in comparison with metabolism by liver microsomes.
Christ W; Hecker W; Junge H; Stille G
Naunyn Schmiedebergs Arch Pharmacol; 1983 Jun; 323(2):176-82. PubMed ID: 6888570
[TBL] [Abstract][Full Text] [Related]
32. Nuclear magnetic resonance and high-performance liquid chromatography-nuclear magnetic resonance studies on the toxicity and metabolism of ifosfamide.
Foxall PJ; Lenz EM; Lindon JC; Neild GH; Wilson ID; Nicholson JK
Ther Drug Monit; 1996 Aug; 18(4):498-505. PubMed ID: 8857575
[TBL] [Abstract][Full Text] [Related]
33. New ifosfamide analogs designed for lower associated neurotoxicity and nephrotoxicity with modified alkylating kinetics leading to enhanced in vitro anticancer activity.
Storme T; Deroussent A; Mercier L; Prost E; Re M; Munier F; Martens T; Bourget P; Vassal G; Royer J; Paci A
J Pharmacol Exp Ther; 2009 Feb; 328(2):598-609. PubMed ID: 19017849
[TBL] [Abstract][Full Text] [Related]
34. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions.
Labroo RB; Paine MF; Thummel KE; Kharasch ED
Drug Metab Dispos; 1997 Sep; 25(9):1072-80. PubMed ID: 9311623
[TBL] [Abstract][Full Text] [Related]
35. Metabolism and pharmacokinetics of oxazaphosphorines.
Boddy AV; Yule SM
Clin Pharmacokinet; 2000 Apr; 38(4):291-304. PubMed ID: 10803453
[TBL] [Abstract][Full Text] [Related]
36. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine.
Lampen A; Zhang Y; Hackbarth I; Benet LZ; Sewing KF; Christians U
J Pharmacol Exp Ther; 1998 Jun; 285(3):1104-12. PubMed ID: 9618413
[TBL] [Abstract][Full Text] [Related]
37. Hydrolytic metabolism of phenyl and benzyl salicylates, fragrances and flavoring agents in foods, by microsomes of rat and human tissues.
Ozaki H; Sugihara K; Tamura Y; Fujino C; Watanabe Y; Uramaru N; Sone T; Ohta S; Kitamura S
Food Chem Toxicol; 2015 Dec; 86():116-23. PubMed ID: 26321725
[TBL] [Abstract][Full Text] [Related]
38. Differential effects of disulfiram and diethyldithiocarbamate on small intestinal and liver microsomal benzo[a]pyrene metabolism.
Grafström R; Greene FE
Biochem Pharmacol; 1980 Jun; 29(11):1517-23. PubMed ID: 6249318
[No Abstract] [Full Text] [Related]
39. Intestinal first-pass metabolism of eperisone in the rat.
Mihara K; Matsumura M; Yoshioka E; Hanada K; Nakasa H; Ohmori S; Kitada M; Ogata H
Pharm Res; 2001 Aug; 18(8):1131-7. PubMed ID: 11587484
[TBL] [Abstract][Full Text] [Related]
40. Decreased oral absorption of cyclosporine A after liver ischemia-reperfusion injury in rats: the contribution of CYP3A and P-glycoprotein to the first-pass metabolism in intestinal epithelial cells.
Ikemura K; Urano K; Matsuda H; Mizutani H; Iwamoto T; Okuda M
J Pharmacol Exp Ther; 2009 Jan; 328(1):249-55. PubMed ID: 18842703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
